Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Published:2018-11 Issue:10160 Volume:392 Page:2180-2193
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Frias Juan Pablo,Nauck Michael A,Van Joanna,Kutner Mark E,Cui Xuewei,Benson Charles,Urva Shweta,Gimeno Ruth E,Milicevic Zvonko,Robins Deborah,Haupt Axel

Publisher

Elsevier BV

Subject

General Medicine

Reference38 articles.

1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

2. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions;Nauck;Lancet Diabetes Endocrinol,2016

3. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007

4. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

5. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial;Tuttle;Lancet Diabetes Endocrinol,2018

Cited by 581 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies;Diseases;2024-09-05

2. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management;Expert Review of Endocrinology & Metabolism;2024-08-28

3. Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health;Frontiers in Pharmacology;2024-08-28

4. Second Generation Anti-Obesity Medications;Current Pediatrics Reports;2024-08-20

5. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19